Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company

Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand

Fineline Cube Feb 2, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...

Company Deals

Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...

Policy / Regulatory

NHSA Launches Service Specifications for Medical Procurement Platform

Fineline Cube Feb 2, 2024

The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement...

Policy / Regulatory

China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement

Fineline Cube Feb 2, 2024

The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement...

Company

WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility

Fineline Cube Feb 1, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Deals

HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development

Fineline Cube Feb 1, 2024

HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...

Company Deals

Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...

Company Deals

Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally

Fineline Cube Feb 1, 2024

Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

Fineline Cube Feb 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...

Company Medical Device

Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment

Fineline Cube Feb 1, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Drug

Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons

Fineline Cube Feb 1, 2024

Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...

Company

WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry

Fineline Cube Feb 1, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...

Company

GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion

Fineline Cube Feb 1, 2024

GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...

Company

Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...

Company Drug

Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval

Fineline Cube Feb 1, 2024

Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...

Company Deals

Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience

Fineline Cube Feb 1, 2024

Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...

Company Deals

Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens

Fineline Cube Feb 1, 2024

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...

Company Deals

Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal

Fineline Cube Feb 1, 2024

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...

Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies

Fineline Cube Feb 1, 2024

MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...

Posts pagination

1 … 428 429 430 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.